ICD indication in hypertrophic cardiomyopathy: which algorithm to use?

Detalhes bibliográficos
Autor(a) principal: Santos-Veloso,Marcelo Antônio Oliveira
Data de Publicação: 2022
Outros Autores: Chaves,Ândrea Virgínia Ferreira, Calado,Eveline Barros, Markman,Manuel, Bezerra,Lucas Soares, Lima,Sandro Gonçalves de, Markman Filho,Brivaldo, Oliveira,Dinaldo Cavalcanti de
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Revista da Associação Médica Brasileira (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302022000801059
Resumo: SUMMARY OBJECTIVE: This study aimed to evaluate the agreement in the indication of implantable cardioverter-defibrillators in patients with Hypertrophic cardiomyopathy, as per the 2014 European Society of Cardiology and 2020 American Heart Association recommendations, and evaluate fragmented QRS as a predictor of cardiovascular outcome. METHODS: Retrospective cohort with 81 patients was evaluated between 2019 and 2021. Patients with hypertrophic cardiomyopathy ≥16 years old were included. Exclusion criteria include secondary myocardiopathy and follow-up <1 year. Kappa coefficient was used to determine the agreement. Survival and incidence curves were determined by Kaplan-Meier method. A p<0.05 was considered significant. RESULTS: The fragmented QRS was identified in 44.4% of patients. There were no differences between patients with and without fragmented QRS regarding clinical parameters, echocardiography, fibrosis, and sudden cardiac death risk. During follow-up of 4.8±3.4 years, there was no sudden cardiac death, but 20.6% patients with implantable cardioverter-defibrillator had at least one appropriate shock. Three of the seven appropriate shocks occurred in European Society of Cardiology low- to moderate-risk patients. Three shocks occurred in moderate-risk patients and four in American Heart Association high-risk patients. Overall recommendations agreement was 64% with a kappa of 0.270 (p=0.007). C-statistic showed no differences regarding the incidence of appropriate shock (p=0.644). CONCLUSION: sudden cardiac death risk stratification algorithms present discrepancies in implantable cardioverter-defibrillator indication, both with low accuracy.
id AMB-1_cc9fdb310ad4c505700909eb779a1d2d
oai_identifier_str oai:scielo:S0104-42302022000801059
network_acronym_str AMB-1
network_name_str Revista da Associação Médica Brasileira (Online)
repository_id_str
spelling ICD indication in hypertrophic cardiomyopathy: which algorithm to use?Sudden cardiac deathHypertrophic cardiomyopathyImplantable cardioverter-defibrillatorCardiac arrhythmiaSUMMARY OBJECTIVE: This study aimed to evaluate the agreement in the indication of implantable cardioverter-defibrillators in patients with Hypertrophic cardiomyopathy, as per the 2014 European Society of Cardiology and 2020 American Heart Association recommendations, and evaluate fragmented QRS as a predictor of cardiovascular outcome. METHODS: Retrospective cohort with 81 patients was evaluated between 2019 and 2021. Patients with hypertrophic cardiomyopathy ≥16 years old were included. Exclusion criteria include secondary myocardiopathy and follow-up <1 year. Kappa coefficient was used to determine the agreement. Survival and incidence curves were determined by Kaplan-Meier method. A p<0.05 was considered significant. RESULTS: The fragmented QRS was identified in 44.4% of patients. There were no differences between patients with and without fragmented QRS regarding clinical parameters, echocardiography, fibrosis, and sudden cardiac death risk. During follow-up of 4.8±3.4 years, there was no sudden cardiac death, but 20.6% patients with implantable cardioverter-defibrillator had at least one appropriate shock. Three of the seven appropriate shocks occurred in European Society of Cardiology low- to moderate-risk patients. Three shocks occurred in moderate-risk patients and four in American Heart Association high-risk patients. Overall recommendations agreement was 64% with a kappa of 0.270 (p=0.007). C-statistic showed no differences regarding the incidence of appropriate shock (p=0.644). CONCLUSION: sudden cardiac death risk stratification algorithms present discrepancies in implantable cardioverter-defibrillator indication, both with low accuracy.Associação Médica Brasileira2022-08-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302022000801059Revista da Associação Médica Brasileira v.68 n.8 2022reponame:Revista da Associação Médica Brasileira (Online)instname:Associação Médica Brasileira (AMB)instacron:AMB10.1590/1806-9282.20220199info:eu-repo/semantics/openAccessSantos-Veloso,Marcelo Antônio OliveiraChaves,Ândrea Virgínia FerreiraCalado,Eveline BarrosMarkman,ManuelBezerra,Lucas SoaresLima,Sandro Gonçalves deMarkman Filho,BrivaldoOliveira,Dinaldo Cavalcanti deeng2022-10-18T00:00:00Zoai:scielo:S0104-42302022000801059Revistahttps://ramb.amb.org.br/ultimas-edicoes/#https://old.scielo.br/oai/scielo-oai.php||ramb@amb.org.br1806-92820104-4230opendoar:2022-10-18T00:00Revista da Associação Médica Brasileira (Online) - Associação Médica Brasileira (AMB)false
dc.title.none.fl_str_mv ICD indication in hypertrophic cardiomyopathy: which algorithm to use?
title ICD indication in hypertrophic cardiomyopathy: which algorithm to use?
spellingShingle ICD indication in hypertrophic cardiomyopathy: which algorithm to use?
Santos-Veloso,Marcelo Antônio Oliveira
Sudden cardiac death
Hypertrophic cardiomyopathy
Implantable cardioverter-defibrillator
Cardiac arrhythmia
title_short ICD indication in hypertrophic cardiomyopathy: which algorithm to use?
title_full ICD indication in hypertrophic cardiomyopathy: which algorithm to use?
title_fullStr ICD indication in hypertrophic cardiomyopathy: which algorithm to use?
title_full_unstemmed ICD indication in hypertrophic cardiomyopathy: which algorithm to use?
title_sort ICD indication in hypertrophic cardiomyopathy: which algorithm to use?
author Santos-Veloso,Marcelo Antônio Oliveira
author_facet Santos-Veloso,Marcelo Antônio Oliveira
Chaves,Ândrea Virgínia Ferreira
Calado,Eveline Barros
Markman,Manuel
Bezerra,Lucas Soares
Lima,Sandro Gonçalves de
Markman Filho,Brivaldo
Oliveira,Dinaldo Cavalcanti de
author_role author
author2 Chaves,Ândrea Virgínia Ferreira
Calado,Eveline Barros
Markman,Manuel
Bezerra,Lucas Soares
Lima,Sandro Gonçalves de
Markman Filho,Brivaldo
Oliveira,Dinaldo Cavalcanti de
author2_role author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Santos-Veloso,Marcelo Antônio Oliveira
Chaves,Ândrea Virgínia Ferreira
Calado,Eveline Barros
Markman,Manuel
Bezerra,Lucas Soares
Lima,Sandro Gonçalves de
Markman Filho,Brivaldo
Oliveira,Dinaldo Cavalcanti de
dc.subject.por.fl_str_mv Sudden cardiac death
Hypertrophic cardiomyopathy
Implantable cardioverter-defibrillator
Cardiac arrhythmia
topic Sudden cardiac death
Hypertrophic cardiomyopathy
Implantable cardioverter-defibrillator
Cardiac arrhythmia
description SUMMARY OBJECTIVE: This study aimed to evaluate the agreement in the indication of implantable cardioverter-defibrillators in patients with Hypertrophic cardiomyopathy, as per the 2014 European Society of Cardiology and 2020 American Heart Association recommendations, and evaluate fragmented QRS as a predictor of cardiovascular outcome. METHODS: Retrospective cohort with 81 patients was evaluated between 2019 and 2021. Patients with hypertrophic cardiomyopathy ≥16 years old were included. Exclusion criteria include secondary myocardiopathy and follow-up <1 year. Kappa coefficient was used to determine the agreement. Survival and incidence curves were determined by Kaplan-Meier method. A p<0.05 was considered significant. RESULTS: The fragmented QRS was identified in 44.4% of patients. There were no differences between patients with and without fragmented QRS regarding clinical parameters, echocardiography, fibrosis, and sudden cardiac death risk. During follow-up of 4.8±3.4 years, there was no sudden cardiac death, but 20.6% patients with implantable cardioverter-defibrillator had at least one appropriate shock. Three of the seven appropriate shocks occurred in European Society of Cardiology low- to moderate-risk patients. Three shocks occurred in moderate-risk patients and four in American Heart Association high-risk patients. Overall recommendations agreement was 64% with a kappa of 0.270 (p=0.007). C-statistic showed no differences regarding the incidence of appropriate shock (p=0.644). CONCLUSION: sudden cardiac death risk stratification algorithms present discrepancies in implantable cardioverter-defibrillator indication, both with low accuracy.
publishDate 2022
dc.date.none.fl_str_mv 2022-08-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302022000801059
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302022000801059
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/1806-9282.20220199
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Associação Médica Brasileira
publisher.none.fl_str_mv Associação Médica Brasileira
dc.source.none.fl_str_mv Revista da Associação Médica Brasileira v.68 n.8 2022
reponame:Revista da Associação Médica Brasileira (Online)
instname:Associação Médica Brasileira (AMB)
instacron:AMB
instname_str Associação Médica Brasileira (AMB)
instacron_str AMB
institution AMB
reponame_str Revista da Associação Médica Brasileira (Online)
collection Revista da Associação Médica Brasileira (Online)
repository.name.fl_str_mv Revista da Associação Médica Brasileira (Online) - Associação Médica Brasileira (AMB)
repository.mail.fl_str_mv ||ramb@amb.org.br
_version_ 1754212837819940864